I am a
Home I AM A Search Login

Papers of the Week

Papers: 7 Jan 2023 - 13 Jan 2023

2023 Jan




Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.


Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, Diamond M, Marmura MJ, Guo H, Finnegan M, Trugman JM
Cephalalgia. 2023 Jan; 43(1):3331024221128250.
PMID: 36620892.


Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of atogepant in participants who completed the phase 3 ADVANCE trial (NCT03777059).